SCHEMBL1934664

SCHEMBL1934664

CCCCCCCCCCCCOC[C@H](O)[C@H]1OC(=O)C(O)=C1O

nearest known ligand 0.67

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 2/20 0.67
TDP1 Q9NUW8 2/20 0.67
HSPD1 P10809 1/20 0.67
HSPE1 P61604 1/20 0.67
TST Q16762 1/20 0.67
RECQL P46063 1/20 0.67
BLM P54132 1/20 0.67
LMNA P02545 1/20 0.55
L3MBTL1 Q9Y468 1/20 0.55
LPAR5 Q9H1C0 2/20 0.43
USP2 O75604 1/20 0.42
HTT P42858 1/20 0.41
LPAR1 Q92633 3/20 0.39
LPAR3 Q9UBY5 3/20 0.39
SPHK1 Q9NYA1 1/20 0.38
PLA2G2C Q5R387 2/20 0.36
ALDH1A1 P00352 1/20 0.36
CYP1A2 P05177 1/20 0.35
CYP3A4 P08684 1/20 0.35
CYP2C19 P33261 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10478307 1.00 MAPT (0.67) MAPTTDP1HSPD1HSPE1TST
SCHEMBL20875130 1.00 MAPT (0.67) MAPTTDP1HSPD1HSPE1TST
SCHEMBL20875134 1.00 MAPT (0.67) MAPTTDP1HSPD1HSPE1TST
SCHEMBL1197734 1.00 MAPT (0.67) MAPTTDP1HSPD1HSPE1TST
SCHEMBL11381977 1.00 MAPT (0.67) MAPTTDP1HSPD1HSPE1TST
SCHEMBL7867820 0.99 MAPT (0.65) MAPTTDP1HSPD1HSPE1TST
Ascorbic Acid SCHEMBL27959253 0.89 MAPT (0.68) MAPTTDP1HSPD1HSPE1TST
SCHEMBL26675671 0.88 MAPT (0.69) MAPTTDP1HSPD1HSPE1TST
SCHEMBL10478250 0.84 MAPT (0.52) MAPTTDP1HSPD1HSPE1TST
SCHEMBL12603053 0.83 MAPT (0.60) MAPTTDP1HSPD1HSPE1TST

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9445992-B2 Mucosal delivery compositions comprising a peptide complexed with a crown compound and/or a counter ion ARISGEN SA (CH) 2016-09-20 US disclosed
CN-102770152-B The mucosal delivery of peptides 阿瑞斯根股份有限公司 2016-07-06 CN disclosed
US-20120302502-A1 MUCOSAL DELIVERY COMPOSITIONS COMPRISING A PEPTIDE COMPLEXED WITH A CROWN COMPOUND AND/OR A COUNTER ION ARISGEN SA (CH) 2012-11-29 US disclosed
CN-102770152-A Mucosal delivery of peptides ARISGEN SA 2012-11-07 CN disclosed
EP-2504019-A2 MUCOSAL DELIVERY COMPOSITION COMPRISING A PEPTIDE COMPLEXED WITH A CROWN COMPOUND AND/OR A COUNTER ION ArisGen SA (CH) 2012-10-03 EP disclosed
WO-2011064316-A2 MUCOSAL DELIVERY OF PEPTIDES BOTTI PAOLO (CH) 2011-06-03 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120302502-A1 MUCOSAL DELIVERY COMPOSITIONS COMPRISING A PEPTIDE COMPLEXED WITH A CROWN COMPOUND AND/OR A COUNTER ION VIP, CFTR, IAPP MAPT 2616/4885TDP1 3594/4885HSPD1 1982/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.